Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

AIM ImmunoTech Inc. (HXB2.F)

0.0610
0.0000
(0.00%)
At close: April 4 at 3:50:39 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for HXB2.F

Recent News: HXB2.F

View More
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
GlobeNewswire 26 days ago
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
GlobeNewswire 28 days ago
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire last month
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GlobeNewswire last month
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
GlobeNewswire 2 months ago
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GlobeNewswire 2 months ago
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
GlobeNewswire 2 months ago
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
GlobeNewswire 2 months ago
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
GlobeNewswire 2 months ago
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
GlobeNewswire 2 months ago
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
GlobeNewswire 2 months ago
View More
Waiting for permission
Allow microphone access to enable voice search

Try again.